low-dose vaginal estrogen for menopause
A review reports that low-dose vaginal estrogen subjectively improves genitourinary syndrome of menopause symptom severity by approximately 60% to 80%.
Hypothesized mechanism
Local estrogen restores estrogen-dependent vaginal and urogenital epithelial tissue, relieving genitourinary menopausal symptoms.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 7 of 10 overall, a moderate reading, from a direct rated moderate in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).
Corroboration
The single source is a review article ('Management of Menopausal Symptoms: A Review'), which provides one synthesis rather than independent replication. A single review scores 1, not 2, since the pooled trials inside it do not count as independent sources.
Rigor
The evidence derives from a review of menopausal symptom management, which functions as a synthesis/review-level source. No specific study design or N is given, but a narrative/systematic review qualifies at the meta-analysis/review tier.
Specificity
The claim names low-dose vaginal estrogen directly and addresses GSM (genitourinary syndrome of menopause), a menopause-related condition. Both intervention and condition are explicitly identified.
Plausibility
Vaginal estrogen plausibly restores estrogen-dependent vaginal/urogenital tissue, addressing GSM symptoms. The mechanism is plausible and clinically established but the quote does not explicitly detail the molecular mechanism, so it remains asserted/plausible rather than evidenced here.
Consistency
Only a single source is provided, so consistency across independent studies cannot be assessed and defaults to neutral (1). The quoted improvement range of 60-80% is internally consistent but not corroborated by additional arms.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Low-dose vaginal estrogen is associated with subjective improvement in GSM symptom severity by approximately 60% to 80% PubMed · PMID 36749328 ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →